• Edwards Lifesciences Corporation Acquires CardiAQ Valve Technologies

    August 26, 2015

    Aug. 26, 2015, Irvine, CA — Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Edwards announced last month that it had signed an agreement to acquire CardiAQ.   Press Release

    Read More
  • Remedy Pharmaceuticals Publication

    July 28, 2015

    July 28, 2015, New York — Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA, a breakthrough drug treating acute central nervous system conditions such as stroke, today announced publication of a peer-reviewed paper that confirms administering CIRARA for pharmacological targeting of the Sur1-Trpm4 channel in human ischemic stroke to reduce blood-brain barrier disruption and cerebral edema is a promising therapeutic strategy. Press Release

    Read More
  • 480 Biomedical, Inc. Receives $1.2M from Broadview

    June 18, 2015

    June 18, 2015, Watertown, MA — 480 Biomedical, Inc., a clinical stage company developing novel bioresorbable scaffold products for the vasculature, announced today $1.2 million in funding from Broadview Ventures. The financing is a second close on a previously announced $10.5 million in Series C funding round from existing investors. The Broadview funds will support the development of a bioresorbable scaffold to treat children with pulmonary artery stenosis (PAS), a narrowing in the branches of the pulmonary artery that reduces blood flow to the lungs and can lead to heart failure. Press R

    Read More
  • Pulmokine Receives $1M from Broadview

    March 3, 2015

    March 3, 2015 Pulmokine announced today that it has entered into an agreement with Broadview Ventures for $1 Million. Proceeds will be used to advance Pulmokine’s lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH). Press Release

    Read More
  • Aria CV, Inc. Raises $6.3M Series A

    December 19, 2014

    December 19, 2014 Aria CV, Inc., Saint Paul, MN—a developer of medical devices to treat heart failure related to pulmonary hypertension, today announced the initial closing of a $6.3 million Series A preferred equity financing. The financing round was led by Catalyst Health Ventures and includes Broadview Ventures and Cedar Point Capital.  The proceeds from this financing will be used to advance development and perform clinical testing of the device. Press Release

    Read More
  • Acesion Pharma Raises 15.2M DKK

    December 17, 2014

    December 17, 2014 Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures. Acesion Pharma, a Danish biotech company developing novel therapeutic treatment for atrial fibrillatin (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity investment round. The round included Boston-based Broadview Ventures as a new investor and current investor Novo Seeds. Press Release

    Read More
  • BioKier Takes a Shot at a New Kind of Diabetes Drug

    August 25, 2014

    August 25, 2014 BioKier Takes a Shot at a New Kind of Diabetes Drug: Chapel Hill, NC, drug developer BioKier is beginning human tests of a drug that, if successful, could replace these injection therapies with a pill that coaxes the body to regulate blood sugar levels on its own, says George Szewczyk, BioKier founder and CEO. If it works, BioKier’s approach could offer some advantages over blockbuster diabetes drugs currently available from big pharmaceutical companies.   Press Release

    Read More
  • Fondation Leducq Profile in Circulation

    August 1, 2014

    Fondation Leducq Circulation Research

    Read More
  • miRagen Therapeutics Extends Research Collaboration with Servier

    June 23, 2014

    June 23, 2014 Servier and miRagen: Servier, an independent French research-based pharmaceutical company with a significant presence in Europe and emerging markets, and miRagen Therapeutics, Inc. a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that they have extended their research collaboration by two years to October 2016 to discover, develop, and commercialize drugs targeting microRNAs for cardiovascular disease. miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNA

    Read More
  • CardiAQ Valve Technologies reports successful FIH implantation

    May 20, 2014

    May 20, 2014 CardiAQ™ Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve. For the 50% of patients suffering from severe, symptomatic Mitral Regurgitation who are denied surgery due to procedural risk, Transcatheter Mitral Valve Implantationmay offer new hope for treatment. With its latest advancement, CardiAQ is now the only company in the TMVI space to have demonstrated procedural success with both Trans-Femoral and Trans-Apical Delivery Systems. Press Release

    Read More